Ferroptosis-centered Disease Response Information
General Information of the Disease (ID: DIS00009)
| Name |
Chronic myeloid leukemia
|
||||
|---|---|---|---|---|---|
| ICD |
ICD-11: 2A20
|
||||
Full List of Target(s) of This Ferroptosis-centered Disease
Unspecific Target
| In total 1 item(s) under this target | ||||
| Experiment 1 Reporting the Ferroptosis-centered Disease Response by This Target | [1] | |||
| Responsed Disease | Chronic myeloid leukemia [ICD-11: 2A20] | |||
| Responsed Regulator | Thioredoxin reductase 1, cytoplasmic (TXNRD1) | Suppressor | ||
| Pathway Response | Fatty acid metabolism | hsa01212 | ||
| Glutathione metabolism | hsa00480 | |||
| Cell Process | Cell ferroptosis | |||
| In Vitro Model | K-562 cells | Chronic myelogenous leukemia | Homo sapiens | CVCL_0004 |
| K562/G01 cells | Chronic myeloid leukemia | Homo sapiens | CVCL_4V47 | |
| Response regulation | TXNRD1 is a key regulator involved in the ferroptosis of chronic myeloid leukemia cells induced by cysteine depletion in vitro. These findings highlight that cysteine depletion serves as a potential therapeutic strategy for overcoming chemotherapy resistance CML. | |||